Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 15/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116686 | 0.87 | NR1H4 (0.55) | RAB9ASMN1; SMN2NR1H4MEN1ALDH1A1 | |
| SCHEMBL10116407 | 0.86 | MAPT (0.48) | MAPTRAB9ASMN1; SMN2MCHR1NR1H4 | |
| SCHEMBL10116720 | 0.84 | MCHR1 (0.43) | MAPTSMN1; SMN2MCHR1NR1H4ALDH1A1 | |
| SCHEMBL10116696 | 0.84 | NR1H4 (0.58) | MAPTRAB9ASMN1; SMN2NR1H4MEN1 | |
| SCHEMBL10116725 | 0.83 | MAPT (0.43) | MAPTRAB9ASMN1; SMN2MCHR1MEN1 | |
| SCHEMBL13566063 | 0.82 | ADRB2 (0.37) | L3MBTL1 | |
| SCHEMBL10116728 | 0.78 | MAPT (0.46) | MAPTMCHR1NR1H4MEN1ALDH1A1 | |
| SCHEMBL14424389 | 0.77 | ACACB (0.42) | RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL10114919 | 0.77 | ACACB (0.42) | RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL10115462 | 0.76 | ALDH1A1 (0.40) | MAPTRAB9ASMN1; SMN2MCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | MAPT 3602/4885RAB9A 3699/4885SMN1; SMN2 2213/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3367/4885RAB9A 3651/4885SMN1; SMN2 2197/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3683/4885RAB9A 3820/4885SMN1; SMN2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.